HC Wainwright Lifts Earnings Estimates for Spyglass Pharma

Spyglass Pharma, Inc. (NASDAQ:SGP) – Analysts at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for Spyglass Pharma in a report issued on Monday, March 30th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.47) for the quarter, up from their previous forecast of ($0.49). HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. HC Wainwright also issued estimates for Spyglass Pharma’s Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.48) EPS and FY2026 earnings at ($2.16) EPS.

Spyglass Pharma (NASDAQ:SGP) last posted its earnings results on Thursday, March 26th. The company reported ($5.72) EPS for the quarter, beating analysts’ consensus estimates of ($6.61) by $0.89.

A number of other research analysts have also recently commented on SGP. Zacks Research raised shares of Spyglass Pharma to a “hold” rating in a research report on Wednesday, March 4th. Citigroup initiated coverage on shares of Spyglass Pharma in a research note on Tuesday, March 3rd. They issued a “buy” rating and a $42.00 price target on the stock. Leerink Partners lowered shares of Spyglass Pharma to a “market perform” rating in a report on Tuesday, March 3rd. Jefferies Financial Group started coverage on shares of Spyglass Pharma in a research report on Tuesday, March 3rd. They set a “buy” rating and a $62.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Spyglass Pharma from a “hold” rating to a “sell” rating in a report on Saturday. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $45.00.

Spyglass Pharma Price Performance

Shares of NASDAQ:SGP opened at $25.91 on Wednesday. Spyglass Pharma has a 12-month low of $20.16 and a 12-month high of $32.44.

Insiders Place Their Bets

In other news, Director Ra Capital Management, L.P. bought 3,690,000 shares of the company’s stock in a transaction on Monday, February 9th. The stock was bought at an average cost of $16.00 per share, with a total value of $59,040,000.00. Following the transaction, the director directly owned 5,966,439 shares in the company, valued at $95,463,024. The trade was a 162.10% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

About Spyglass Pharma

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).